Johnson & Johnson has halted its Phase 2 field study of mosnodenvir, an investigational antiviral for dengue prevention, due to strategic reprioritization of its R&D portfolio.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.